have an even higher risk of developing TB and transmitting nosocomial infection. 3, 6 The Academic Unit for Infection Prevention and Control (UIPC), based in the University of Stellenbosch, Western Cape, South Africa, has set up an IPC programme with specifi c policies and in-service training to reduce TB transmission among patients, visitors and health care workers in a central academic hospital (CAH) in Cape Town. IPC at the CAH includes contextspecifi c administrative processes (protocols, segregation and isolation of infectious patients), ventilation (natural and mechanical) and the use of personal protective equipment (PPE), such as masks, respirators and gloves. 3 It has been shown that the implementation of administrative controls, environmental controls and PPE effectively reduces transmission of TB in health care facilities. 6 Although TB care in South Africa is mainly community-based, prevalence surveys and fi eld observations show that a signifi cant number of patients continue to present to hospitals. 7 At the CAH, TB patients are often admitted due to comorbidities, such as HIV/ AIDS and treatment for drug-resistant TB.
The emergence of multidrug-resistant (MDR-) and extensively drug-resistant TB (XDR-TB) are of particular concern to IPC and health care cost management. These TB strains are resistant to the main antituberculosis drugs, and require a longer treatment regimen of 20 months or more, resulting in higher treatment costs. 8 Reduction in TB, including MDR-and XDR-TB, is dependent on effective diagnosis, treatment and improved communications between the hospital, the laboratory and its down-referral clinics. 9 In South Africa, no studies assessing the costs of in-patient-based TB care, including diagnosis, management and IPC, have been published. In a resourcelimited environment, an adequate costing study is necessary for data on the cost implications of IPC per patient diagnosed and treated. 10 It was therefore important for the UIPC to investigate the cost of inp atient TB management, including the use of TB-IPC, in the CAH. This study will fi ll an important gap in the literature by providing cost estimates of in-patientbased TB care and by identifying areas of weakness in IPC measures. Furthermore, cost reduction per TB case prevented can be determined.
The objectives of the study were to estimate the costs associated with the management (diagnosis, treatment, IPC) of pulmonary TB in-patients at a CAH, and to evaluate adherence to TB-IPC protocol recommendations, such as PPE use, during pulmonary TB in-patient care at a CAH.
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Health solu ons for the poor 
S
outh Africa ranks fi fth among the 22 high tuberculosis (TB) burden countries in terms of incidence, and seventh in terms of overall TB burden. The 2011 World Health Organization report on TB indicates a prevalence of 795 per 100 000 population and an incidence of 981/100 000 in South Africa. 1 At 1000/ 100 000 population, the Western Cape Province has the highest recorded TB incidence in South Africa. 2 TB is the most common opportunistic infection and the leading cause of death in persons with HIV/AIDS (human immunodefi ciency virus/acquired immunedefi ciency syndrome). [3] [4] [5] TB infection prevention and control (IPC) is a combination of processes and measures aimed at minimising the risk of TB transmission, both in health care facilities and at the community level. Effective management of TB in hospitals is essential to prevent transmission among patients, health care workers and visitors. 5 Health care workers are at higher risk due to frequent exposure to patients with TB. The number of persons with HIV/AIDS attending health care facilities has increased in South Africa; such persons are at an increased risk of developing TB. Moreover, if health care workers themselves are immune-suppressed they
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METHODOLOGY

Design
A retrospective and partly prospective cost analysis was performed. The analysis was conducted from a provider's perspective, as we examined the costs to the health service, including inp atient processes and hospital care. This means that all direct and non-direct health care costs were included; however, direct nonhealth care costs, such as patient travel and time costs, were excluded. [11] [12] [13] The unit cost of health services was defi ned as the full economic costs per patient treated. 11, 12 To be able to determine the costs in as detailed a manner as possible, the ingredient-based costing method was used, i.e., each component of TB management was calculated and a unit cost was derived for each. 10 For this, cost-analysis market prices were used, as they represented the most precise estimation of the costs in daily practice. 11 Costs were expressed in terms of monetary value (2009 US$).
Data collection
TB management costs at the CAH consisted of in-patient days, laboratory tests, medications and PPE, including masks, respirators, gloves, aprons and disinfectant. To calculate the costs of an in-patient day, we used the basic accounting system at the hospital, including all patients admitted and treated for pulmonary TB during the period from May 2008 to October 2009. Accounting heads were used to determine in-patient day costs; the costs were then added up and divided by the patient-day equivalent (PDE). PDE was calculated by adding the number of in-p atients plus one third of out-patient visits. This ratio is based on primary data collected from Western Cape hospitals, which assumes that an inp atient day requires three times more overhead resources than an out-patient day. 14 In other words, this ratio provides information on the costs of one day of hospital admission or three out-patient visits. The components of the costs of an in-p atient stay are listed in Table 1 . Costs for laboratory tests and medications were not i ncluded in calculating the cost of an in-p atient day, as we chose to calculate these costs specifi cally for TB.
Other costs included diagnostic laboratory tests and drug prescriptions. Clinicom, an electronic patient database, was accessed to identify patients diagnosed and admitted to the hospital with pulmonary TB between May 2008 and October 2009. A total of 200 patients were included in the study.
To determine laboratory costs, we used the National Health Laboratory Service (NHLS) database. This is updated daily, capturing laboratory test requests for each patient. For patients found in the Clinicom database, we selected only TB-specifi c laboratory tests, as shown in Table 2 . TB-specifi c medication data were extracted from the electronic database of the hospital pharmacy (Table 3). The laboratory test prices from the NHLS and medication prices from the pharmacy were used to determine the prices of the items identifi ed and measured.
Use of personal protective equipment
In line with the TB-IPC protocol of the hospital, all in-patients with pulmonary TB were reported to the IPC nursing team. PPE use per day was measured using several randomly selected observations on the wards by the principal investigator. The type and quantity of PPE used by personnel and visitors when in contact with TB patients were documented. These observations were used to investigate the volume of PPE for the costing analysis and to evaluate the TB-IPC protocol. Nine patients were observed for 24 h each, spread over a time period of 4 weeks. 
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Data analysis
The cost of an in-patient day and that of a day of PPE use were multiplied by the average length of stay of a TB patient at the hospital; this was then added to laboratory and medication costs. We used a ZAR-USD exchange rate of 1 ZAR = USD 0. 
RESULTS
In-patient day costs were calculated using all patients with pulmonary TB at the hospital. The average cost of an in-patient day was US$238 (95% confi dence interval [CI] 193-238; range 205-299; Table 4 ).
Laboratory and medication costs
Of the 200 TB patients included in the analysis, 24.5% (n = 49) had no records in either the NHLS or the pharmacy database, and a value of zero was therefore used for their laboratory and medication costs. These patients were included in the differential analysis as they received treatment and were perceived to represent in-patient costs for pulmonary TB at the hospital most accurately. Mean laboratory costs were US$26.82 (95%CI 36.59-90.22, range 0.00-174.88). Patients with high costs underwent several costly laboratory tests, possibly when MDR-TB was suspected. No data on the defi nitive diagnosis (i.e., susceptible or resistant) of these patients were available. Mean medication costs were US$8.68 (95%CI 34.88-52.23, range 0.00-133.36). Patients with high laboratory costs often also had higher medication costs.
Costs of personal protective equipment
The average cost of a day of PPE use was US$0.99 (95%CI 0.26-1.72, range 0.42-1.40). PPE costs for suspected MDR-TB cases were slightly higher than for drug-susceptible TB, as more masks were used. PPE included surgical masks, gloves, aprons and hand disinfectant. N95 respirators were not used, although these were recommended for MDR-TB cases (Table 5) .
Total tuberculosis management costs
Using a random sample of 70 TB patients from our population, we calculated the average length of stay to be 9.7 days (range 0-47). The length of the study lent itself to a point prevalence analysis, which gave an idea of the average length of stay during the time period. The in-patient day costs and cost of one day of PPE use were multiplied by the average length of stay and added to laboratory and medication costs. The total TB management costs for an in-patient with TB, using a length of stay of 0 days and one of 47 days, were respectively US$36 and US$11 246. The average cost of an in-patient TB stay at the hospital was US$2373 ( Figure) .
Use of personal protective equipment
The use of surgical masks can serve as an indicator of adherence to TB-IPC protocol, as they have to be worn when entering the patient's room. The use of other types of PPE, such as gloves and aprons, is compulsory during clinical procedures and does not indicate adherence to the TB-IPC protocol. Staff wore a mask during 26.3% of the room entries, compared to only 15.8% for visitors (Table 5) . It was observed during data collection that a patient with suspected MDR-TB left the isolation room without permission. On another occasion, another MDR-TB suspect was not admitted to an isolation room. These observations suggest that IPC measures and PPE use were not always applied in clinical practice despite TB-IPC protocol recommendations. 
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DISCUSSION
A number of policy recommendations can be formulated from our study results. Our fi ndings show that the total in-patient TB management costs at the hospital were on average US$2373 per TB patient, and that the main cost driver was the large number of in-patient days (97%). Laboratory tests, medication and PPE costs represented a much lower proportion. In general, the cost of TB control as a proportion of public health expenditure is relatively low. 1 To reduce costs, the duration of in-patient stay should be shortened. It is, however, impossible to say where cost savings may be made on the basis of this study alone. An effi ciency assessment of the TB management programme has to be made before any recommendations can be proposed on cost reduction concerning in-patient days. The literature shows that community-based TB management is more cost-effective than clinic-based care. 15 The cost of communitybased TB care in South Africa is estimated to be approximately US$392-US$766 per patient. 15 It is diffi cult to compare these costs with the costs found in our study, as hospitalisation is often required for complex cases, such as MDR-TB patients and those with comorbidities (HIV/AIDS). This could be a reason for the high costs found in our study. It is not our intention to suggest that such patients should be treated in the community, unless they are well stabilised. Community-based treatment should not be seen as an alternative to in-patient care. More research is needed for information about the cost-effectiveness of both treatment options.
We identifi ed problems with adherence to the TB-IPC protocol in terms of the appropriate use of PPE, which is critical for the prevention of transmission and nosocomial TB infection. 6 We may conclude that the overall use of PPE (especially masks) was poor among staff (26.3%), and even more so among visitors (15.8%). Patients with suspected MDR-TB were poorly monitored by staff. It should also be noted that PPE costs represented only a small proportion of the total costs (0.4%). This small investment could lead to major changes. If PPE is used optimally, new cases can be prevented, resulting in considerable cost reductions. For each TB case prevented using IPC measures, the hospital could save on average US$2373. Emphasis on PPE implementation is therefore important. Other options for improving adherence to the TB-IPC protocol should be investigated.
This study has some limitations that should be addressed in future research. First, it did not address the effi ciency and effectiveness of anti-tuberculosis treatment at the hospital. Second, a substantial part of our study population did not have a record of costs at the NHLS or the pharmacy database. The laboratory and medication costs were slightly higher when these patients were excluded. Third, the cost of HIV/AIDS management was not included. In South Africa, 53% of patients with TB are tested for HIV and of these, 60% are co-infected. The literature available on additional costs due to HIV co-infection is limited. The costs of HIV/AIDS management are known; however, due to the chronic nature of the disease, it is diffi cult to associate the additional costs incurred by TB patients. Further studies should include the extra costs for HIV/AIDS diagnosis and treatment. We assumed that TB-HIV co-infection led to longer duration of hospital stay. In this study, HIV prevalence was diffi cult to measure due to the stigma attached to HIV/AIDS in South Africa and unclear notations in patients' medical records.
Fourth, we assumed that patients who received different prescriptions and large quantities of medication were suspected MDR-TB cases, as treatment costs for MDR-TB are substantially higher than for drug-susceptible TB. 8 Recent data show that 1.8-6.7% of pulmonary TB patients in South Africa have MDR-TB. 1 These patients account for higher laboratory costs due to drug susceptibility testing. Unfortunately, in our population the defi nitive diagnosis (TB or MDR-TB) was unknown. We do know that MDR-TB is associated with higher PPE costs. The literature shows that MDR-TB requires a prolonged treatment regimen, which means that these patients would have an increased length of stay. 8 As in-patient day costs account for most of our TB management costs, the costs for MDR-TB treatment should be much higher.
In conclusion, this study shows that the costs associated with in-patient TB management at a CAH in South Africa are high. It is important to investigate whether anti-tuberculosis treatment FIGURE Total tuberculosis management costs at the central academic hospital. In-patient day costs per day and PPE costs per day were multiplied by average length of stay (9.7 days). PPE = personal protective equipment. 
Marco de referencia:
En Sudáfrica se notifican más casos de tuberculosis (TB) que en ningún otro país, pero no se cuenta con un cál-culo actualizado y preciso de los costos generados por el diagnóstico, el tratamiento y la prevención de la TB a escala intrahospitalaria. Objetivo: Determinar los costos asociados con el manejo de los pacientes hospitalizados por TB en un hospital universitario central en la Ciudad del Cabo. Se evaluó además la utilización de los dispositivos personales de protección (PPE). Método: Se llevó a cabo un estudio de costos, retrospectivo y parcialmente prospectivo, del tratamiento de los pacientes hospitalizados por TB entre mayo del 2008 y octubre del 2009. Resultados: El costo promedio por día de hospitalización fue US$238 y la duración promedio de la estancia fue 9,7 días. El promedio de los costos de laboratorio por hospitalización fue US$26,82 y el promedio de los costos por medicamentos fue US$8,68. El costo del uso de los dispositivos personales de protección fue US$0,99 por día. El promedio del costo total del tratamiento de la TB fue US$2373. El PPE no siempre se utilizó de manera adecuada. Conclusión: Los costos del tratamiento intrahospitalario de la TB son altos en comparación con los costos del manejo comunitario. La principal razón del alto costo fue la prolongación de la estancia. Es preciso realizar una evaluación de la eficiencia, a fin de obtener recomendaciones que contribuyan a disminuir los costos. La disminución de costos por cada caso de TB que se logra prevenir es de cerca de US$2373. El uso de los dispositivos personales de protección representó la categoría con más bajo costo en el presupuesto. Es necesario impartir capacitación sobre la utilización de estos PPE.
